Supernus achieved record total revenues of $211.6 million in Q4 2025, a 21% increase year-over-year. Despite the revenue growth, the company reported a GAAP operating loss and net loss for the quarter, primarily due to acquisition-related costs from the Sage Therapeutics transaction. However, non-GAAP adjusted operating earnings remained stable at $48.5 million.

Supernus Pharmaceuticals reported a 4% increase in total revenues to $149.8 million for the first quarter of 2025, driven by strong growth in Qelbree® and GOCOVRI® sales. Despite an increase in operating loss, adjusted operating earnings saw a significant rise. The company also successfully launched ONAPGO™.

Supernus Pharmaceuticals reported a strong fourth quarter and full year 2024, driven by substantial increases in Qelbree and GOCOVRI net product sales. Total revenues for Q4 2024 reached $174.2 million, with operating earnings of $21.4 million and diluted EPS of $0.27. The company also announced the FDA approval of ONAPGO, with a planned launch in Q2 2025.

Supernus Pharmaceuticals reported a 14% increase in total revenue for Q3 2024, driven by strong sales of Qelbree and GOCOVRI. Operating earnings significantly improved compared to the same period in the previous year. The company also announced positive topline data from its Phase 2a study of SPN-820 in major depressive disorder and initiated a Phase 1 study for SPN-443.

Supernus Pharmaceuticals announced strong financial results for the second quarter of 2024, marked by a 24% increase in total revenues to $168.3 million compared to the same period in 2023. Key growth drivers were Qelbree and GOCOVRI, with Qelbree net sales increasing by 92% and GOCOVRI by 10%. The company also reported an operating income of $22.6 million and adjusted operating earnings of $45.5 million. Supernus raised its full-year 2024 guidance for total revenues and operating earnings.

Supernus Pharmaceuticals reported Q1 2024 financial results, with total revenues of $143.6 million and a net income of $0.1 million. Qelbree net sales increased by 75% compared to Q1 2023. The company reiterated its full-year 2024 financial guidance.

Supernus Pharmaceuticals reported a decrease in total revenues for Q4 2023, primarily due to the decline in net product sales of Trokendi XR, which was partially offset by increases in net product sales of Qelbree and GOCOVRI. The company is focused on transitioning to growth products and anticipates several clinical milestones in 2024.

Supernus Pharmaceuticals reported total revenues of $153.9 million for Q3 2023. Qelbree net product sales increased by 103% compared to Q3 2022, and GOCOVRI net product sales increased by 18% compared to Q3 2022. The company raised its full-year 2023 adjusted operating earnings guidance to $95 million to $110 million.

Supernus Pharmaceuticals reported a decrease in total revenues for Q2 2023, primarily due to the decline in Trokendi XR sales. However, Qelbree and GOCOVRI net product sales experienced growth, with combined sales increasing by 67% compared to the same period last year. The company reiterates its full year 2023 financial guidance.

Supernus Pharmaceuticals reported first quarter 2023 total revenues of $153.8 million, a slight increase compared to $152.5 million in the first quarter of 2022. Excluding Trokendi XR, net product sales increased by 25%. The company's GAAP operating earnings were $5.2 million, and non-GAAP operating earnings were $30.5 million. The company raised its full year 2023 GAAP and non-GAAP operating earnings guidance.

Supernus Pharmaceuticals reported a 6% increase in net product sales for the fourth quarter of 2022, reaching $163.8 million, driven by growth in Qelbree and GOCOVRI sales. The company's full-year revenues reached a record $667.2 million, a 15% increase compared to the previous year. The company anticipates approximately 30% growth at the midpoint of full year 2023 total revenues guidance compared to full year 2022, excluding revenues of Trokendi XR®.

Supernus Pharmaceuticals, Inc. announced financial results for the third quarter of 2022. Total revenues increased by 19% compared to the same period in 2021. The company is raising its full-year 2022 operating earnings and total revenues guidance. Qelbree prescriptions and net product sales continued to grow.

Supernus Pharmaceuticals, Inc. announced its Q2 2022 financial results, with total revenues of $170.1 million, a 20% increase compared to Q2 2021. The company reported GAAP operating earnings of $11.3 million and non-GAAP operating earnings of $37.6 million. Qelbree prescriptions continued to grow, with a 33% increase compared to Q1 2022.

Supernus Pharmaceuticals reported a strong first quarter in 2022, with a 16% increase in total revenues to $152.5 million compared to Q1 2021. Net earnings and diluted earnings per share (GAAP) were $25.6 million and $0.43, respectively. The FDA approved Qelbree for ADHD treatment in adults, and Qelbree prescriptions increased by 38% compared to Q4 2021.

Supernus Pharmaceuticals reported total revenues of $159.1 million and net earnings of $2.4 million for Q4 2021. Operating earnings were $6.1 million. The company reiterated its full-year 2022 financial guidance.

Supernus Pharmaceuticals reported Q3 2021 total revenues of $148.5 million, a 4% decrease compared to $155.1 million in Q3 2020. Net earnings were $21.6 million, or $0.40 per diluted share, compared to $40.0 million, or $0.74 per diluted share, for the same period in 2020.

Supernus Pharmaceuticals reported a revenue increase of 12% compared to 2020. The company launched Qelbree for pediatric ADHD and submitted an sNDA for adult ADHD. Operating earnings decreased compared to the same period last year.

Supernus Pharmaceuticals reported a strong first quarter in 2021, with total revenues reaching $130.9 million, a 38% increase compared to the same period in 2020. Net product sales were $128.4 million, a 39% increase year-over-year. The company's operating earnings were $13.2 million, and net earnings were $5.7 million, or $0.11 per diluted share.

Supernus Pharmaceuticals reported Q4 2020 net product sales of $140.7 million, a 44% increase compared to the same period in 2019. The company's full year 2020 total revenues were $520.4 million, a 32% increase compared to 2019. Supernus is preparing for the expected launch of SPN-812 in the second quarter of 2021.

Supernus Pharmaceuticals reported Q3 2020 total revenues of $155.1 million, including net product sales of $152.1 million. Operating earnings were $56.1 million, and net earnings were $40.0 million, or $0.74 per diluted share. The company increased its full-year 2020 net product sales guidance range to $500 million to $525 million and operating earnings guidance range to $145 million to $160 million.

Supernus Pharmaceuticals reported a strong second quarter in 2020, with total revenue reaching $126.7 million, driven by net product sales of Trokendi XR, Oxtellar XR, and acquired Parkinson’s disease products. The company also completed the acquisition of the CNS portfolio of US WorldMeds and executed a Development and Option Agreement with Navitor Pharmaceuticals, Inc.

Supernus Pharmaceuticals reported a strong first quarter in 2020 with total revenue reaching $95.0 million, an 11% increase compared to 2019. The company is on track for the launch of SPN-812 and is expanding its portfolio through strategic acquisitions and partnerships.

Supernus Pharmaceuticals reported Q4 2019 financial results, with net product sales at $97.9 million and operating earnings at $40.8 million.